Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Short-course all-oral bedaquiline-based regimen for multidrug-resistant tuberculosis in China
ChiCTR2100042204Phase 4Recruiting
- Sponsor
- Shanghai Pulmonary Hospital
- Start
- Jan 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of bedaquiline in multidrug-resistant tuberculosis (MDR-TB) (2 arms), sponsored by Shanghai Pulmonary Hospital. Primary endpoint: treatment success rate. Started Jan 2021; status: recruiting.
02
Drugs
bedaquiline
03
Conditions
multidrug-resistant tuberculosis (MDR-TB)
Beyond the preview
Go deeper on ChiCTR2100042204.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100042204.